CVAC · CureVac
Acquired Company
BioNTech acquired CureVac N.V. on 12/18/2025 in an all-stock transaction valued at approximately US $1.25 billion.
CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany.
FRIEDRICH-MIESCHER-STRASSE 15, TÜBINGEN, GERMANY, 72076, Tübingen, 72076, USA
BIOTECHNOLOGY
HEALTHCARE
Market Cap
1.049B
52 Wk Range
$4.00 - $5.55
Previous Close
$4.66
Open
$4.66
Volume
N/A
Day Range
$4.66 - $4.66
Enterprise Value
599.3M
Cash
416.1M
Avg Qtr Burn
N/A
Insider Ownership
0.10%
Institutional Own.
10.43%
Qtr Updated
Sep 30th 2025